Paper Contents
Abstract
Atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), has become a critical component in the therapeutic arsenal against non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases. This antibody works by inhibiting the interaction between PD-L1 and its receptor PD-1 on T-cells, thereby reactivating the immune system to recognize and attack cancer cells. The emergence of atezolizumab as a significant therapeutic option has been marked by its ability to improve survival rates and provide durable responses in patients with advanced and metastatic NSCLC, making it a cornerstone of immunotherapy in this setting.This review provides a comprehensive examination of the clinical outcomes and safety profile of atezolizumab in NSCLC patients. By analyzing data from pivotal clinical trials such as IMpower150, IMpower130, and OAK, as well as real-world studies, this review aims to elucidate the effectiveness of atezolizumab across various treatment lines and patient subgroups, including those with different levels of PD-L1 expression. The review highlights the substantial survival benefits observed with atezolizumab, particularly when used in combination with chemotherapy or as a monotherapy in PD-L1 high-expressing tumors. It also explores the role of atezolizumab in both first-line and second-line settings, offering insights into its versatility as a treatment option.Furthermore, the review delves into the safety profile of atezolizumab, discussing both the common adverse events, such as fatigue, nausea, and decreased appetite, and the more serious immune-related adverse events (irAEs), including pneumonitis, hepatitis, and colitis. By balancing the discussion of efficacy with an in-depth analysis of potential risks, this review provides a critical overview of atezolizumab's role in the evolving treatment landscape of NSCLC, helping to inform clinical decision-making and patient management.
Copyright
Copyright © 2024 Dr. Sumaiya Taj. This is an open access article distributed under the Creative Commons Attribution License.
